The California Supreme Court sided with Gilead Sciences in a closely watched case over whether the company had a "duty" to innovate.

Ação movida por pacientes questionava a interrupção de um novo remédio para HIV com menos efeitos colaterais

The California Supreme Court sided with Gilead Sciences in a closely watched case over whether the company had a "duty" to innovate.